These findings provide important insight into the role of TSP-1 in context of NAFLD/NASH that may ultimately lead to identification of future anti-fibrotic therapeutics against NAFLD. This evidence concerns the gene THBS1 and metabolic dysfunction-associated steatotic liver disease.